27. A kit comprising a first formulation comprising an effective amount of: an inodilator selected from the group consisting of pimobendan and levosimendan and pharmaceutically or veterinary acceptable salts thereof, and a second formulation comprising an effective amount of an angiotensin converting enzyme inhibitor selected from the group consisting of enalapril, benazepril, cilazapril, delapril, imidapril, moexipril, spirapril, temocapril, trandolapril, ramipril, quinapril, perindopril, lisinopril and pharmaceutically and veterinary acceptable salts thereof, wherein the first and second formulations are held separately and the first formulation comprises at least 7 wt% of the total formulation of propylene glycol.

28. A kit comprising a first formulation comprising: an effective amount of an inodilator selected from the group consisting of pimobendan and levosimendan and pharmaceutically or veterinary acceptable salts thereof and a second formulation comprising a further active agent, wherein the first and second formulations are held separately and the first formulation comprises at least 7 wt% of the total formulation of propylene glycol.

29. Use of the liquid formulation of any one of claims 1 to 25 in the manufacture of a medicament for the treatment of cardiac disease and/or hypertension in a patient in need thereof.

30. The use of claim 29, wherein cardiac disease is a primary heart disease selected from the group consisting of: congestive heart failure (CHF), acute CHF, chronic CHF, decompensated endocardiosis (DCE), dilated cardiomyopathy (DCM), asymptomatic (occult) CHF, asymptomatic DCM, and chronic valvular heart disease, or a combination thereof.

31. The use of claim 29, wherein cardiac disease is a secondary heart disease and is selected from the group consisting of: cardiovascular dysfunction and impaired renal perfusion during anaesthesia, shock, gastric dilation, volvulus, myocardial ischaemia, and renal ischaemia, or a combination thereof.

32. The use of any one of claims 29 to 31, wherein the medicament is to be administered orally.

33. The use of any one of claims 29 to 31, wherein the medicament is to be administered parenteral.